|Articles|August 10, 2022
- Pharmaceutical Executive-08-01-2022
- Volume 42
- Issue 8
Pharmaceutical Executive, August 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
The Silver Lining Of Innovation in Genetic Medicineover 3 years ago
Navigating the Financial Meltdown for Biopharmaover 3 years ago
The Potential of Proteomicsover 3 years ago
Getting ‘Personal’ With Vaccine Developmentover 3 years ago
A World of Opportunityover 3 years ago
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
3
Report: Richard Pazdur Out as Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
